GLP-1 RA Drugs Show Promise, but Limitations Remain
A study of 1.2 million medical records found that GLP-1 RA drugs, such as Ozempic and Wegovy, may reduce the risk of several health issues, including substance use disorders, psychiatric disorders, and dementia, by 8-18%, but also carry risks of nausea, vomiting, and pancreatic or kidney complicatio...
GLP-1 RA Drugs Show Promise, but Limitations Remain
A study of 1.2 million medical records found that GLP-1 RA drugs, such as Ozempic and Wegovy, may reduce the risk of several health issues, including substance use disorders, psychiatric disorders, and dementia, by 8-18%, but also carry risks of nausea, vomiting, and pancreatic or kidney complicatio...
Progress
44% Bias Score
GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions
A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...
GLP-1RA Drugs Show Potential Link to Reduced Risk of Mental Health and Cognitive Conditions
A study of over 1.2 million veterans' medical records suggests a possible link between GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, and a reduced risk of various mental health conditions, including suicidal thoughts, schizophrenia, dementia, and Alzheimer's disease, although further res...
Progress
44% Bias Score
GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
GLP-1 Drugs Show Significant Health Benefits and Risks in Large-Scale Study
A study of over two million veterans found that GLP-1 drugs, such as Ozempic, significantly reduce risks of neurocognitive disorders, addiction, and self-harm, but also increase the risk of pancreatic and kidney problems.
Progress
52% Bias Score
Shift Work's Health Impacts: Risks, Adaptability, and Schedule Optimization
Shift work, especially night shifts, significantly impacts health, increasing risks of various diseases, including cancer, and disrupting sleep patterns. Adaptability varies with age and chronotype, with forward-rotating shifts and shorter workweeks recommended to minimize risks.
Shift Work's Health Impacts: Risks, Adaptability, and Schedule Optimization
Shift work, especially night shifts, significantly impacts health, increasing risks of various diseases, including cancer, and disrupting sleep patterns. Adaptability varies with age and chronotype, with forward-rotating shifts and shorter workweeks recommended to minimize risks.
Progress
52% Bias Score
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes revealed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues, including cardiovascular problems and infections, but increased risks of gastrointestinal issues and low blood pressure.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes revealed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues, including cardiovascular problems and infections, but increased risks of gastrointestinal issues and low blood pressure.
Progress
40% Bias Score
GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study
A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...
GLP-1 Drugs Show Unexpected Health Impacts in Large-Scale Study
A study of 215,970 diabetic patients using GLP-1 receptor antagonist drugs found lower risks of 42 conditions (including cardiovascular disease, bacterial infections, and Alzheimer's) and higher risks of 19 (including nausea, low blood pressure, and joint pain) compared to other treatments; further ...
Progress
16% Bias Score
Diabetes Drugs Linked to Reduced Risk of Mental Health Issues
A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...
Diabetes Drugs Linked to Reduced Risk of Mental Health Issues
A study of 1.2 million veterans' medical records found that the diabetes and weight-loss drugs Ozempic and Wegovy (GLP-1 receptor agonists) may be linked to a reduced risk of various mental health issues, including alcohol and substance use disorders, suicidal thoughts, schizophrenia, dementia, and ...
Progress
24% Bias Score
Samsung's Non-Invasive CGM: A Potential Game Changer
Samsung announced it is developing a non-invasive, optical continuous glucose monitor (CGM), a significant advancement in wearable health technology, potentially launching in a future Galaxy Watch or as a standalone device within the next year.
Samsung's Non-Invasive CGM: A Potential Game Changer
Samsung announced it is developing a non-invasive, optical continuous glucose monitor (CGM), a significant advancement in wearable health technology, potentially launching in a future Galaxy Watch or as a standalone device within the next year.
Progress
52% Bias Score
Sugary Drinks Linked to Millions of Diabetes and Cardiovascular Disease Cases Globally
A study in Nature Medicine estimates that 2.2 million new type 2 diabetes cases and 1.2 million new cardiovascular disease cases worldwide in 2020 are potentially linked to sugary drinks, with sub-Saharan Africa, Latin America, and the Caribbean showing the highest proportions; researchers suggest i...
Sugary Drinks Linked to Millions of Diabetes and Cardiovascular Disease Cases Globally
A study in Nature Medicine estimates that 2.2 million new type 2 diabetes cases and 1.2 million new cardiovascular disease cases worldwide in 2020 are potentially linked to sugary drinks, with sub-Saharan Africa, Latin America, and the Caribbean showing the highest proportions; researchers suggest i...
Progress
40% Bias Score
Weight-Loss Drugs Show Reduced Alzheimer's Risk, But Increased Gastrointestinal Issues
A study of over two million US diabetic patients found that GLP-1 receptor agonist weight-loss drugs like Wegovy and Ozempic reduced the risk of Alzheimer's by 12%, drug/alcohol dependence, and some blood clotting issues, but increased risks of gastrointestinal problems, low blood pressure, and kidn...
Weight-Loss Drugs Show Reduced Alzheimer's Risk, But Increased Gastrointestinal Issues
A study of over two million US diabetic patients found that GLP-1 receptor agonist weight-loss drugs like Wegovy and Ozempic reduced the risk of Alzheimer's by 12%, drug/alcohol dependence, and some blood clotting issues, but increased risks of gastrointestinal problems, low blood pressure, and kidn...
Progress
32% Bias Score
High Blood Pressure and Diabetes Prevalence and Prevention in the US
Approximately half of US adults have high blood pressure, and over 10% have diabetes, significantly increasing heart disease and stroke risks; early diagnosis and treatment, even without symptoms, are crucial, with lifestyle changes and medications offering effective management.
High Blood Pressure and Diabetes Prevalence and Prevention in the US
Approximately half of US adults have high blood pressure, and over 10% have diabetes, significantly increasing heart disease and stroke risks; early diagnosis and treatment, even without symptoms, are crucial, with lifestyle changes and medications offering effective management.
Progress
16% Bias Score
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
GLP-1 Receptor Agonists: Significant Health Benefits and Risks Revealed in Large-Scale Study
A study of 1.4 million US veterans with type 2 diabetes showed that GLP-1 receptor agonists, weekly-injected drugs, reduced the risk of 42 health issues but increased the risk of 19 others, highlighting both benefits and risks of this increasingly popular medication.
Progress
36% Bias Score